JP2019533645A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533645A5
JP2019533645A5 JP2019514781A JP2019514781A JP2019533645A5 JP 2019533645 A5 JP2019533645 A5 JP 2019533645A5 JP 2019514781 A JP2019514781 A JP 2019514781A JP 2019514781 A JP2019514781 A JP 2019514781A JP 2019533645 A5 JP2019533645 A5 JP 2019533645A5
Authority
JP
Japan
Prior art keywords
protein
agents
protein nanocage
nanocage
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019514781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533645A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/052079 external-priority patent/WO2018053434A1/en
Publication of JP2019533645A publication Critical patent/JP2019533645A/ja
Publication of JP2019533645A5 publication Critical patent/JP2019533645A5/ja
Pending legal-status Critical Current

Links

JP2019514781A 2016-09-16 2017-09-18 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ Pending JP2019533645A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395852P 2016-09-16 2016-09-16
US62/395,852 2016-09-16
PCT/US2017/052079 WO2018053434A1 (en) 2016-09-16 2017-09-18 Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery

Publications (2)

Publication Number Publication Date
JP2019533645A JP2019533645A (ja) 2019-11-21
JP2019533645A5 true JP2019533645A5 (https=) 2020-10-08

Family

ID=60002019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514781A Pending JP2019533645A (ja) 2016-09-16 2017-09-18 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ

Country Status (4)

Country Link
US (1) US11090391B2 (https=)
EP (1) EP3512563A1 (https=)
JP (1) JP2019533645A (https=)
WO (1) WO2018053434A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108503704A (zh) * 2017-02-27 2018-09-07 昆山新蕴达生物科技有限公司 穿越血脑屏障的纳米药物载体
CN112367974A (zh) * 2018-05-15 2021-02-12 DNALite治疗学公司 粘液穿透肽、递送媒介和治疗方法
WO2020077060A1 (en) * 2018-10-10 2020-04-16 University Of Washington High-polymer-density bioconjugate compositions and related methods
US12577292B2 (en) * 2019-03-07 2026-03-17 Kyungpook National University Industry-Academic Cooperation Foundation Ferritin nanocage for multi-displaying trail trimer and cancer-targeting peptide and use thereof as anticancer agent
WO2021045210A1 (ja) * 2019-09-05 2021-03-11 味の素株式会社 ペプチド内包フェリチン
KR20210053252A (ko) * 2019-11-01 2021-05-11 (주)셀레메디 면역 관문 분자와 결합 가능한 분자가 융합된 단백질 및 이의 용도
WO2021086159A1 (ko) * 2019-11-01 2021-05-06 (주)셀레메디 면역 관문 분자와 결합 가능한 분자가 융합된 단백질 및 이의 용도
WO2021086158A1 (ko) * 2019-11-01 2021-05-06 (주)셀레메디 질환 항원이 융합된 단백질 및 이의 용도
KR102658825B1 (ko) * 2020-10-23 2024-04-19 경북대학교 산학협력단 Pd-l1 결합 펩타이드 1을 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도
CN112972421B (zh) * 2021-02-26 2022-04-08 清华大学 基于多正电荷蛋白的纳米药物系统、其制备方法及应用
CN115160559B (zh) * 2021-04-02 2024-02-02 杭州宜生医药科技发展有限公司 一种peg化雷帕霉素化合物及其制备方法与应用
WO2024228598A1 (ko) * 2023-05-04 2024-11-07 경북대학교 산학협력단 Lag3 결합 펩타이드를 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도
CN119326734B (zh) * 2024-12-17 2025-06-06 浙江大学 一种铁蛋白纳米颗粒及其药物递送系统的组装方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US6699475B1 (en) 1987-09-02 2004-03-02 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
KR920003787B1 (ko) 1990-03-05 1992-05-14 한국과학기술 연구원 신규 플라스미드 제조 및 그를 함유한 균주를 배양하여 아이 지 에프-1(igf-1)을 생산하는 방법
US5571711A (en) 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5821122A (en) 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
CA2341897A1 (en) 1998-08-28 2000-03-09 Uropath Pty. Ltd. Method of diagnosis of prostate cancer
CA2369433A1 (en) 1999-02-26 2000-08-31 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6673545B2 (en) 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
CA2611861C (en) 2005-06-08 2017-11-28 The Brigham And Women's Hospital, Inc. Methods and compositions for the treatment of persistent infections
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US20070258889A1 (en) 2005-11-09 2007-11-08 Montana State University Novel nanoparticles and use thereof
US8575359B2 (en) 2006-04-04 2013-11-05 The Regents Of The University Of California Acid-sensitive linkers for drug delivery
KR101523391B1 (ko) 2006-12-27 2015-05-27 에모리 유니버시티 감염 및 종양 치료를 위한 조성물 및 방법
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CL2008003526A1 (es) 2007-11-30 2010-01-11 Medarex Inc Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer.
JPWO2010029947A1 (ja) * 2008-09-09 2012-02-02 国立大学法人京都大学 造影剤組成物及びその製造方法
BR112013021732B1 (pt) * 2011-02-25 2021-11-30 South Dakota State University Micela estável e utilização da micela estável
BR112014014262A2 (pt) * 2011-12-14 2017-06-13 Univ Johns Hopkins nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
WO2014031727A1 (en) 2012-08-21 2014-02-27 Brown University Ferritin-based tumor targeting agent, and imaging and treatment methods
EP3197920B1 (en) * 2014-09-25 2021-01-13 Nanyang Technological University Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages

Similar Documents

Publication Publication Date Title
JP2019533645A5 (https=)
US12611461B2 (en) Bioorthogonal compositions
JP2025066807A (ja) 生体直交型組成物
US20180085321A1 (en) Solid nanoparticle with inorganic coating
JPWO2020122034A5 (https=)
JP2010513526A5 (https=)
JP2012532185A5 (https=)
WO2016206540A1 (zh) 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
JP2008529539A5 (https=)
JP2015519330A5 (https=)
JP2013512889A5 (https=)
JP2009500431A5 (https=)
US20240335548A1 (en) Macromolecules
JP2009508936A (ja) 活性物質の標的化送達用ナノ粒子
CN105491999A (zh) 用于癌症治疗的多西他赛聚合纳米颗粒
JP2019533038A (ja) 改善されたハイブリッドテロデンドリマー
JP2017119721A (ja) 併用療法用ナノ粒子
EP3883934A1 (en) Therapeutic dendrimer
JP2016509586A5 (https=)
JP2021523912A5 (https=)
CN116133693B (zh) 载药的大分子及其制备方法
WO2012138730A1 (en) Drug delivery compositions and methods
JP2026500527A (ja) 脂質化合物ならびにその製造方法及び使用方法
KR20220092557A (ko) 펩티드-나노입자 접합체
JP2023145581A (ja) インターロイキン－２３受容体のペプチド阻害剤の組成物